Abgenix, Lexicon Genetics Inc. deal
The companies will use LEXG's mammalian assays to validate drug targets against which ABGX will generate human antibodies. ABGX will have access to LEXG's OmniBank library of knockout mouse clones. LEXG will receive a fee for each knockout mouse it develops for ABGX and will receive license fees for each gene ABGX selects for antibody development from OmniBank. LEXG also will be eligible for milestone and royalty payments on antibodies ABGX develops from OmniBank genes and from other LEXG knockout mouse models to which ABGX has an exclusive license. LEXG will retain rights to therapeutics other than antibodies developed from targets selected. This is the second drug discovery alliance between the companies (see BioCentury, July 17, 2000). ...